Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
World Journal of Surgery
Erschienen in: World Journal of Surgery 9/2014

01.09.2014

Graft Vessel Disease Following Heart Transplantation: A Systematic Review of the Role of Statin Therapy

verfasst von: Robin Som, Peter J. Morris, Simon R. Knight

Erschienen in: World Journal of Surgery | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Graft vessel disease (GVD) is a significant cause of morbidity and mortality in cardiac allograft recipients. Hyperlipidemia is a risk factor for GVD, and the majority of patients will display abnormal lipid profiles in the years following transplant.

Objective

This systematic review aims to establish the clinical impact of statins in cardiac allograft recipients, critically appraising the literature on this subject.

Methods

A literature search for randomized studies assessing statin use in cardiac allograft recipients was undertaken. The Cochrane Central Registry of Controlled Trials, MEDLINE, EMBASE, clinicaltrials.gov, and the Transplant Library from the Centre for Evidence in Transplantation were searched. The primary outcome was presence of GVD. Secondary outcomes included graft and patient survival, acute rejection, and adverse events. Meta-analysis was precluded by heterogeneity in outcome reporting and therefore narrative synthesis was undertaken.

Results

Seven randomized controlled trials (RCTs) were identified. The majority of RCTs demonstrated some risk of bias, and methods of outcome measurement were variable. Studies reporting incidence or severity of GVD suggest that statins do confer benefit. Survival benefit from statin use is modest. There is a low incidence of adverse events attributable to statins. There was no difference in the overall number of episodes of rejection.

Conclusion

Whilst the methodological quality of evidence describing the use of statins in cardiac allograft recipients is limited, the available evidence suggests benefit from their use. This is compatible with the effects of statins in non-transplant patients with cardiovascular disease. Furthermore, the rate of adverse events in the trials is low.
Literatur
1.
Miller LW, Schlant RC, Kobashigawa JA et al (1993) 24th Bethesda conference: cardiac transplantation: task force 5: complications. J Am Coll Cardiol 22:41–54PubMedCrossRef
2.
Keogh A, Simons L, Spratt P et al (1988) Hyperlipidaemia after heart transplantation. J Heart Transplant 7:171–175PubMed
3.
Taylor DO, Edwards LB, Boucek MM et al (2007) Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplantation report-2007. J Heart Lung Transplant 26:769–781PubMedCrossRef
4.
Stehlik J, Edwards LB, Kucheryavaya AY et al (2010) The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report: 2010. J Heart Lung Transplant 29:1089–1103PubMedCrossRef
5.
Becker DM, Chamberlain B, Swank R et al (1988) Relationship between corticosteroid exposure and plasma lipid levels in heart transplant patients. Am J Med 85:632–638PubMedCrossRef
6.
Ballantyne CM, Podet EJ, Patsch WP et al (1989) Effect of cyclosporine therapy on plasma lipoprotein levels. JAMA 262:53–56PubMedCrossRef
7.
Costanzo MR, Naftel DC, Pritzker MR et al (1998) Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 17:744–753PubMed
8.
Raichlin ER, McConnell JP, Lerman A et al (2007) Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy. J Heart Lung Transplant 26:826–833PubMedCrossRef
9.
Eich D, Thompson JA, Ko DJ et al (1991) Hypercholesterolemia in long term survivors of heart transplantation. J Heart Lung Transplant 10:45–49PubMed
10.
Sharples LD, Caine N, Mullins P et al (1991) Analysis of survival data after transplantation and its risk factors for graft loss. Transplant Proc 23:1167–1169PubMed
11.
Gao SZ, Alderman EL, Schroeder JS et al (1988) Accelerated coronary vascular disease in heart transplant patients: coronary arteriographic findings. J Am Coll Cardiol 12:334–340PubMedCrossRef
12.
Gao SZ, Schroeder JS, Alderman EL et al (1987) Clinical and laboratory correlates of accelerated coronary artery disease in cardiac transplant patients. Circulation 76:56–61
13.
McGriffin DC, Savumen T, Kirklin JK et al (1995) Cardiac transplant coronary disease: a multivariate analysis of pretransplant risk factors for disease development and morbid events. J Thorac Cardiovasc Surg 109:1081–1089CrossRef
14.
Uretsky BF, Murali S, Reddy PS et al (1987) Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisolone. Circulation 76:827–834PubMedCrossRef
15.
Taylor DO, Edwards LB, Boucek MM et al (2006) Registry of the International Society for Heart and Lung Transplantation: twenty third official adult heart transplantation report—2006. J Heart Lung Transplant 25:869–879PubMedCrossRef
16.
Wang SS (2008) Treatment and prophylaxis of cardiac allograft vasculopathy. Transplant Proc 40:2609–2610PubMedCrossRef
17.
Segovia J, Gómez-Bueno M, Alonso-Pulpón L (2006) Treatment of allograft vasculopathy in heart transplantation. Expert Opin Pharmacother 7:2369–2383PubMedCrossRef
18.
Park JW, Merz M, Braun P et al (1996) Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant 15:572–579PubMed
19.
Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809PubMedCrossRef
20.
Colvin-Adams M, Harcourt N, Duprez D (2013) Endothelial dysfunction and cardiac allograft vasculopathy. J Cardiovasc Transl Res 6:263–277PubMedCrossRef
21.
Rahmani M, Cruz RP, Granville DJ et al (2006) Allograft vasculopathy versus atherosclerosis. Circ Res 99:801–815PubMedCrossRef
22.
23.
Adams D, Russell M, Hancock W et al (1993) Chronic rejection in experimental cardiac transplantation: studies in Lewis-F344 model. Immunol Rev 134:5–19PubMedCrossRef
24.
Ciubotariu R, Colovai A, Pennesi G et al (1998) Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+ CD28−regulatory T cells. J Immunol 161:5193–5202PubMed
25.
Salomon RN, Hughes C, Schoen F et al (1991) Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 138:791–798PubMedCentralPubMed
26.
Zhang X, Kelemen S, Eisen H (2000) Quantitative assessment of cell adhesion molecule gene expression in endomyocardial biopsy specimens from cardiac transplant recipients using competitive polymerase chain reaction. Transplantation 70:505–513PubMedCrossRef
27.
Rose EA, Smith CR, Petrossian GA, Barr ML, Reemstma K (1989) Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis. Surgery 106:203–207PubMed
28.
Rose ML (1996) Role of antibody and indirect antigen presentation in transplant associated coronary artery vasculopathy. J Heart Lung Transplant 15:342–349PubMed
29.
Russell PS, Chase CM, Winn HJ et al (1994) Coronary atherosclerosis in transplanted mouse hearts II.Importance of humoral immunity. J Immunol 152:5135–5142PubMed
30.
Valantine HA (2003) Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant “atheroma”. Transplantation 76:891–899PubMedCrossRef
31.
Caforio ALP, Tona F, Fortina AB et al (2004) Immune and non-immune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant 4:962–970PubMedCrossRef
32.
Nagji AS, Hranjec T, Swenson BR et al (2010) Donor age is associated with chronic allograft vasculopathy after adult heart transplantation: implications for donor allocation. Ann Thorac Surg 90:168–175PubMedCentralPubMedCrossRef
33.
Pratschke J, Neuhaus P, Tullius S (2005) What can be learned from brain-death models? Transpl Int 18:15–21PubMedCrossRef
34.
Johnson MR (1992) Transplant coronary disease: non-immunologic risk factors. J Heart Lung Transplant 11:S124–S132PubMed
35.
Hillbrands LB, Demacker P, Hoitsma AJ et al (1995) The effect of cyclosporine and prednisone on serum and lipid (apo) lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 5:2073–2081
36.
Kasiske B, Tortorice K, Heim-Duthoy K et al (1991) The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 17:700–707PubMedCrossRef
37.
Fish RD, Nabel EG, Selwyn AP et al (1988) Responses of coronary arteries of cardiac transplant patients to acetylcholine. J Clin Invest 81:21–31PubMedCentralPubMedCrossRef
38.
Hollenberg SM, Klein LW, Parrillo JE et al (2001) Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 104:3091–3096PubMedCrossRef
39.
Hirohata A, Nakamura M, Waseda K et al (2007) Changes in coronary anatomy and physiology after heart transplantation. Am J Cardiol 99:1603–1607PubMedCrossRef
40.
Davis SF, Yeung AC, Meredith IT et al (1996) Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year post transplant. Circulation 93:457–462PubMedCrossRef
41.
Hollenberg SM, Klein LW, Parrillo JE et al (2004) Changes in coronary endothelial function predict progression of allograft vasculopathy after heart transplantation. J Heart Lung Transplant 23:265–271PubMedCrossRef
42.
Weis M, Hartmann A, Olbrich HG et al (1998) Prognostic significance of coronary flow reserve on left ventricular ejection fraction in cardiac transplant recipients. Transplantation 65:103–108PubMedCrossRef
43.
Sudhir K, MacGregor JS, DeMarco T et al (1994) Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation 90:3018–3023PubMedCrossRef
44.
Abraham RT, Karnitz LM, Burns LA et al (1994) Proximal signals and the control of S-phase entry in interleukin-2-stimulated T lymphocytes. Adv Exp Med Biol 365:197–210PubMedCrossRef
45.
Diederich D, Skopec J, Diederich A et al (1994) Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 23:957–961PubMedCrossRef
46.
47.
Laufs U, Fata VL, Plutzky J et al (1998) Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 97:1129–1135PubMedCrossRef
48.
Chan WW, Wong GT, Irwin MG (2013) Perioperative statin therapy. Expert Opin Pharmacother 14:831–842PubMedCrossRef
49.
Kotze MJ, van Rensburg SJ (2012) Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer’s disease. Metab Brain Dis 27:255–266PubMedCentralPubMedCrossRef
50.
Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423PubMedCentralPubMedCrossRef
51.
The Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389
52.
Nissen S, Nicholls S, Sipahi I et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295:1556–1565PubMedCrossRef
53.
Kobashigawa JA, Katznelson S, Laks H et al (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621–627PubMedCrossRef
54.
Wenke K, Meiser B, Thiery J et al (2003) Simvastatin early after heart transplantation: 8-year prospective experience. Circulation 107:93–97PubMedCrossRef
55.
Mehra MR, Uber PA, Vivekananthan K et al (2002) Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 40:1609–1614PubMedCrossRef
56.
Keogh A, McDonald P, Kaan A et al (2000) Efficacy and safety of pravastatin vs. simvastatin after cardiac transplantation. J Heart Lung Transplant 19:529–537PubMedCrossRef
57.
Kobashigawa JA, Moriguchi JD, Laks H et al (2005) Ten–year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24:1736–1740PubMedCrossRef
58.
59.
Biggs MJ, Bonser RS, Cram R (2005) Localized rhabdomyolysis after exertion in a cardiac transplant recipient on statin therapy. J Heart Lung Transplant 25:356–357CrossRef
60.
Rodriguez JA, Crespo-Leiro MG, Paniagua MJ et al (1999) Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. Transplant Proc 31:2522–2523PubMedCrossRef
61.
De Denus S, Al-Jazairi A, Loh E et al (2004) Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients. Ann Pharmacother 38:1136–1141PubMedCrossRef
62.
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700PubMedCentralPubMedCrossRef
63.
Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef
64.
Ambrosi P, Aillaud MF, Habib G et al (2000) Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. Thromb Haemost 83:46–48PubMed
65.
O’Rourke B, Barbir M, Mitchell AG et al (2004) Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study. Int J Cardiol 94:235–240PubMedCrossRef
66.
Wenke K, Meiser B, Thiery J et al (1997) Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 96:1398–1402PubMedCrossRef
67.
See VY Jr, DeNofrio D, Goldberg L et al (2003) Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction. Am J Cardiol 92:11–15PubMedCrossRef
68.
Billingham ME, Cary NRB, Hammond EH et al (1990) A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart Rejection Study Group. J Heart Transplant 9:587–593PubMed
69.
Stewart S, Winters GL, Fishbein MC et al (2005) Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24:1710–1720PubMedCrossRef
70.
Mehra MR, Ventura HO, Chambers R et al (1995) Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 26:1537–1544PubMedCrossRef
71.
Schmid C, Kerber S, Baba HA et al (1997) Graft vascular disease after heart transplantation. Eur Heart J 18:554–559PubMedCrossRef
72.
Parameshwar J, Foote J, Sharples L et al (1996) Lipids, lipoprotein (a) and coronary artery disease in patients following cardiac transplantation. Transpl Int 9:481–485PubMedCrossRef
73.
Weis M, Pehlivanli S, Meiser B et al (2001) Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 38:814–818PubMedCrossRef
74.
Mach F (2002) Statins as immunmodulators. Transplant Immunol 9:197–200CrossRef
75.
Katznelson S, Wang XM, Chia D et al (1998) The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 17:335–340PubMed
76.
Cutts JL, Scallen TJ, Watson J et al (1989) Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 139:550–557PubMedCrossRef
77.
Cutts JL, Bankhurst AD (1990) Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 145:244–252PubMedCrossRef
78.
Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207PubMedCrossRef
79.
Li H, Tanaka K, Oeser B et al (2006) Vascular remodelling after cardiac transplantation: a 3-year serial intravascular ultrasound study. Eur Heart J 27:1671–1677PubMedCrossRef
80.
Kobashigawa JA, Tobis JM, Starling RC et al (2005) Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 45:1532–1537PubMedCrossRef
81.
Pasternak RC, Smith SC, Bairey-Merz CN et al (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40:567–572PubMedCrossRef
82.
Bramow S, Ott P, Thomsen NF et al (2001) Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (rapamycin). Pharmacol Toxicol 89:133–139PubMedCrossRef
83.
Olbricht C, Wanner C, Eisenhauer T et al (1997) Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62:311–321PubMedCrossRef
84.
Bruckert E, Hayem G, Dejager S et al (2005) Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 19:403–414PubMedCrossRef
85.
Ballantyne CM, Radovancevic B, Farmer JA et al (1992) Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 19:1315–1321PubMedCrossRef
86.
Ballantyne CM, Corsini A, Davidson MH et al (2003) Risk for myopathy with statin therapy in high risk patients. Arch Intern Med 163:553–564PubMedCrossRef
87.
Corpier CL, Jones PH, Suki WN et al (1988) Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 260:239–241PubMedCrossRef
88.
Maltz HC, Balog DL, Cheigh JS (1999) Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 33:1176–1179PubMedCrossRef
89.
Kusus M, Stapleton DD, Lertora JJ et al (2000) Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci 320:394–397PubMedCrossRef
90.
Stehlik J, Edwards LB, Kucheryavaya AY et al (2012) The registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012. J Heart Lung Transplant 31:1052–1064PubMedCrossRef
91.
Thompson PD, Clarkson PM, Rosenson RS (2006) An assessment of statin safety by muscle experts. Am J Cardiol 97:69C–76CPubMedCrossRef
92.
Southworth MR, Mauro VF (1997) The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother 31:489–491PubMed
93.
Billingham ME (1987) Cardiac transplant arteriosclerosis. Transplant Proc 19:19–25PubMed
94.
Scanlon PJ, Faxon DP, Audet AM et al (1999) ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 33:1756–1824PubMedCrossRef
95.
Johnson DE, Gao SZ, Schroeder JS et al (1989) The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant 8:349–359PubMed
96.
Mehra MR, Crespo-Leiro MG, Dipchand A et al (2010) International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy: 2010. J Heart Lung Transplant 29:717–727PubMedCrossRef
97.
Wallace CK, Stetson SJ, Küçüker SA et al (2005) Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients. J Heart Lung Transplant 24:46–51PubMedCrossRef
98.
Park SJ, Kang SJ, Ahn JM et al (2012) Visual-functional mismatch between coronary angiography and fractional flow reserve. JACC Cardiovasc Interv 5:1029–1036PubMedCrossRef
99.
Meiser BM, Wenke K, Thiery J et al (1995) Prevention and treatment of graft vessel disease after heart transplantation. Transplant Proc 27:1931–1935PubMed
100.
Reichart B, Meiser BM, Wenke K et al (1995) What is the role of lipid lowering therapy in heart-allograft failure? Kidney Int 52:S52–S55
101.
Wenke K, Meiser B, Thiery J et al (1995) Is a reduction of graft vessel disease by maximal treatment of hypercholesterolemia after heart transplantation possible? Transplant Proc 27:1954–1955PubMed
102.
Vivekananthan K, Mehra MR, Uber PA et al (2002) Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation. J Assoc Physicians India 0:682–684
Metadaten
Titel
Graft Vessel Disease Following Heart Transplantation: A Systematic Review of the Role of Statin Therapy
verfasst von
Robin Som
Peter J. Morris
Simon R. Knight
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
World Journal of Surgery / Ausgabe 9/2014
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-014-2543-x

Weitere Artikel der Ausgabe 9/2014

World Journal of Surgery 9/2014 Zur Ausgabe

OriginalPaper

Inter-Rater Reliability of the PIPES Tool: Validation of a Surgical Capacity Index for Use in Resource-Limited Settings

OriginalPaper

Sexual Function and Body Image are Similar after Laparoscopy-Assisted and Open Ileal Pouch–Anal Anastomosis

Letter

Primary Hyperparathyroidism: An Analysis of Failure of Parathyroidectomy

OriginalPaper

Long-Term Quality of Life after Ivor Lewis Esophagectomy for Esophageal Cancer

OriginalPaper

Assessing Surgical Quality: Comparison of General and Procedure-Specific Morbidity Estimation Models for the Risk Adjustment of Pancreaticoduodenectomy Outcomes

OriginalPaper

A Modification of Radical Antegrade Modular Pancreatosplenectomy for Adenocarcinoma of the Left Pancreas: Significance of En Bloc Resection Including the Anterior Renal Fascia

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise